AREDs (age-related eye disease study)
Roc has taken AREDs daily for years to reduce the risk of macular degeneration. The AREDs formula was developed by a long clinical trial at Johns Hopkins University. Results from the Age-Related Eye Disease Study (AREDS) indicated that supplementation with antioxidants (β-carotene and vitamins C and E) and zinc was associated with a reduced risk of AMD progression. The AREDS2 follow-up study, designed to improve upon the earlier formulation, tested the addition of lutein, zeaxanthin, and ω-3 fatty acids. Dietary interventions reduce risk and progression of macular degeneration: Age-related macular degeneration (AMD) is one of the leading causes of vision loss in the elderly.
Zinc 80 mg Lutein 10 mg Zeaxanthin 2 mg Vitamin C 500 mg. Vitamin E 180 mg Copper 2 mg
The amount of vitamin E in AREDs2 is optimal for rejuvenating the immune system of people over age 65. A study by Simin Meydani et al that compared 60, 200, and 800 mg daily. They demonstrated that the 200 mg dosage was superior in elevating the immune response in elderly participants, and it is especially important to note that there were no adverse effects seen in this study, as has been consistently true for vitamin E. “88 free-living, healthy subjects at least 65 years old… were randomly assigned placebo or 60, 200, or 800 mg/d of vitamin E for 235 days… Subjects consuming 200 mg/d of vitamin E had a 65% increase in [immune cells]… No adverse effects were observed with vitamin E supplementation.” Meydani, S.N., et al. “Vitamin E supplementation and in vivo immune response in health elderly subjects”, JAMA 277: 1380-86 (1997))
I have found no reasons to not take AREDsII.
